Bupropion-Cysteine Molecular Complex for Excipient Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bupropion, a commonly used antidepressant and smoking cessation drug, is prone to instability in the presence of common excipients, leading to potential degradation and reduced efficacy.
Innovation Solution
Formulating bupropion with cysteine in a molecular complex at specific molar ratios, which stabilizes the drug and enhances its stability in the presence of excipients, thereby improving its pharmaceutical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If bupropion is formulated with common excipients, then the pharmaceutical composition can be manufactured and administered, but the bupropion becomes unstable and degrades
Solution Approach 1:
Cysteine acts as a stabilizing agent or intermediary substance that protects bupropion from degradation in the presence of common excipients. The cysteine forms a molecular complex with bupropion, creating a stable association that prevents the harmful interaction between bupropion and excipients while allowing the pharmaceutical composition to be manufactured and administered.
2Device complexity
If bupropion is used alone, then the formulation is simple, but the drug stability is reduced leading to degradation
Solution Approach 1:
The invention creates a composite molecular complex consisting of bupropion and cysteine. This composite structure combines two substances to achieve stability that neither component achieves alone. The molecular complex maintains the therapeutic activity of bupropion while adding the stabilizing properties of cysteine, resulting in a reliable pharmaceutical composition.
3Stability of the object's composition
If cysteine is added to stabilize bupropion, then the stability increases, but the formulation complexity increases
Solution Approach 1:
The invention optimizes the molar ratio parameter of bupropion to cysteine to achieve maximum stability with minimal formulation complexity. By establishing a specific stoichiometric relationship (particular molar ratios), the formulation achieves effective stabilization without requiring excessive amounts of additional components, thus limiting the increase in formulation complexity.
Data Source
AI summary
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.